title: Targeted therapy: resistance and re-sensitization.
abstract: The last two decades have witnessed a paradigm shift from cytotoxic drugs to targeted therapy in medical oncology and pharmaceutical innovation. Inspired by breakthroughs in molecular and cellular biology, a number of novel synthesized chemical compounds and recombinant antibodies have been developed to selectively target oncogenic signaling pathways in a broad array of tumor types. Although targeted therapeutic agents show impressive clinical efficacy and minimized adverse effects compared with traditional treatments, the challenging drug-resistant issue has also emerged to limit their benefits to cancer patients. In this regard, we aim to improve targeted therapy by presenting a systematic framework regarding the drug resistance mechanisms and alternative approaches to re-sensitize cancer cells/tissues therapeutically.
authors.affiliation: Biomedical Research Institute, Yiling Pharmaceutical Company, Beijing, 102600, P. R. China. daohong@hotmail.com.
authors.forename: Dao-Hong
authors.initials: DH
authors.lastname: Chen
authors.affiliation: Biotherapy Center, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, P. R. China. zhangxsh@sysucc.org.cn.
authors.forename: Xiao-Shi
authors.initials: XS
authors.lastname: Zhang
mesh_terms: D000970:Antineoplastic Agents; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009369:Neoplasms; D015398:Signal Transduction
chemical_list: D000970:Antineoplastic Agents